The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
Pfizer made one thing clear this week: It's officially back in the obesity race.
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.
Pfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss ...
Considerable on MSN
Lilly’s Zepbound seen beating Pfizer injection
Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results